About Us
Premium Insights
Expert Views
Compliance
Experts
Careers
Contact Us
Our Expert Views content provides the ideal narrative for businesses, subject matter experts, and those interested in the expert network industry's latest trends and talking points. These in-depth perspectives cover various industries, business verticals, sectors, and regions, supporting our global clientele.
Head Of Strategy | Business & Operation
Ever wondered how thousands of medical samples travel safely from homes and clinics to testing labs? Discover the smart hub-and-spoke system powering efficient specimen movement—where logistics precision meets healthcare speed.
Vice President, Partner Development (Sept 2022 - Apr 2023)
What began as a TV link between two hospitals is now rewriting healthcare’s future. Explore how telehealth rose from niche to necessity, breaking barriers in access, technology, and global collaboration—ushering in a smarter, more connected world of care.
Senior Manager & Head - Analytical R&D (Vaccines & Biologicals) (Aug 2021 - Present)
Pandemics push the vaccine industry to the edge—high risks, tight deadlines, and uncertain outcomes. Discover how crises like COVID-19 challenge manufacturers and spark innovation, revealing whether pandemics are a threat or the next big opportunity.
Director
South Africa’s healthcare funding is shifting. Affordable private insurance now joins traditional medical schemes, opening access, creating business opportunities, and reshaping how care is delivered. Learn how this dual-economy reality is transforming the market.
Cluster Head - Karnataka & Tamil Nadu Operations (Apr 2021 - Aug 2022)
Healthcare is evolving fast — and data analytics is its new heartbeat. From reducing medical errors to predicting diseases before they turn critical, analytics empowers smarter, safer, and more cost-efficient care. Discover how data is reshaping the future of healthcare delivery.
Senior General Manager, Research and Development (Sept 2017 - Feb 2023)
Democrats push affordable meds for seniors, but biosimilars face hurdles. While generics cut $338B in costs, new rules may slow biosimilar adoption and impact innovation. Explore how policy, pricing, and competition shape the future of accessible treatments.